Department of Pharmacology, Drug Development and Therapeutics, University of Turku, Turku, Finland.
J Nucl Med. 2014 Mar;55(3):466-72. doi: 10.2967/jnumed.113.125625. Epub 2014 Feb 10.
It remains unclear how different translocator protein (TSPO) ligands reflect the spatial extent of astrocyte or microglial activation in various neuroinflammatory conditions. Here, we use a reproducible lipopolysaccharide (LPS)-induced model of acute central nervous system inflammation to compare the binding performance of a new TSPO ligand (18)F-GE-180 with (11)C-(R)-PK11195. Using immunohistochemistry, we also explore the ability of the TSPO ligands to detect activated microglial cells and astrocytes.
Lewis rats (n = 30) were microinjected with LPS (1 or 10 μg) or saline (1 μL) into the left striatum. The animals were imaged in vivo at 16 h after the injection using PET radiotracers (18)F-GE-180 or (11)C-(R)-PK11195 (n = 3 in each group) and were killed afterward for autoradiography of the brain. Immunohistochemical assessment of OX-42 and glial fibrillary acidic protein (GFAP) was performed to identify activated microglial cells and reactive astrocytes.
In vivo PET imaging revealed an increase in the ipsilateral TSPO binding, compared with binding in the contralateral hemisphere, after the microinjection of 10 μg of LPS. No increase was observed with vehicle. By autoradiography, the TSPO radiotracer binding potential in the injected hemisphere was increased after striatal injection of 1 or 10 μg of LPS. However, the significant increase was observed only when using (18)F-GE-180. The area of CD11b-expressing microglial cells extended beyond that of enhanced GFAP staining and mapped more closely to the extent of (18)F-GE-180 binding than to (11)C-(R)-PK11195 binding. The signal from either PET ligand was significantly increased in regions of increased GFAP immunoreactivity and OX-42 colocalization, meaning that the presence of both activated microglia and astrocytes in a given area leads to increased binding of the TSPO radiotracers.
(18)F-GE-180 is able to reveal sites of activated microglia in both gray and white matter. However, the signal is increased by the presence of activated astrocytes. Therefore, (18)F-GE-180 is a promising new fluorinated longer-half-life tracer that reveals the presence of activated microglia in a manner that is superior to (11)C-(R)-PK11195 due to the higher binding potential observed for this ligand.
目前尚不清楚不同的转位蛋白(TSPO)配体如何反映各种神经炎症情况下星形胶质细胞或小胶质细胞激活的空间范围。在这里,我们使用一种可重复的脂多糖(LPS)诱导的急性中枢神经系统炎症模型,比较新型 TSPO 配体(18)F-GE-180 与(11)C-(R)-PK11195 的结合性能。我们还使用免疫组织化学方法探索 TSPO 配体检测激活的小胶质细胞和星形胶质细胞的能力。
将 LPS(1 或 10 μg)或生理盐水(1 μL)微注射到左侧纹状体,将 30 只 Lewis 大鼠(每组 3 只)进行体内成像,注射后 16 h 使用 PET 放射性示踪剂(18)F-GE-180 或(11)C-(R)-PK11195 进行成像,并在死后进行大脑放射性自显影。进行 OX-42 和胶质纤维酸性蛋白(GFAP)的免疫组织化学评估,以识别激活的小胶质细胞和反应性星形胶质细胞。
与对侧半球相比,微注射 10 μg LPS 后,同侧 TSPO 结合增加。在载体组中未观察到增加。通过放射性自显影,在纹状体注射 1 或 10 μg LPS 后,注射半球的 TSPO 放射性示踪剂结合潜能增加。然而,仅在用(18)F-GE-180 时观察到显著增加。表达 CD11b 的小胶质细胞的区域扩展超出了增强的 GFAP 染色区域,并与(18)F-GE-180 结合的范围比(11)C-(R)-PK11195 结合的范围更密切。在增加的 GFAP 免疫反应性和 OX-42 共定位区域,两种 PET 配体的信号均显著增加,这意味着在给定区域中存在激活的小胶质细胞和星形胶质细胞会导致 TSPO 放射性示踪剂结合增加。
(18)F-GE-180 能够显示灰质和白质中激活的小胶质细胞的部位。然而,由于观察到更高的结合潜能,因此信号会因激活的星形胶质细胞的存在而增加。因此,(18)F-GE-180 是一种有前途的新型氟代长半衰期示踪剂,由于观察到该配体的更高结合潜能,它以优于(11)C-(R)-PK11195 的方式揭示了激活的小胶质细胞的存在。